Title:
METHOD FOR PREVENTING AND/OR TREATING THROMBOEMBOLIC DISEASES
Document Type and Number:
WIPO Patent Application WO/2023/098637
Kind Code:
A1
Abstract:
The present invention relates to a method for preventing and/or treating thromboembolic diseases, comprising the following step: administering a coagulation factor XI (FXI) binding protein to a subject in need thereof, which binding protein can comprise at least one immunoglobulin single variable domain capable of specifically binding to FXI, wherein the at least one immunoglobulin single variable domain may comprise CDR1, CDR2 and CDR3 in a VHH as shown in any one of SEQ ID NOs: 4, 10 and 14.
Inventors:
XU TING (CN)
YIN QUN (CN)
YAN RONGMEI (CN)
LI QIAN (CN)
WANG YAN (CN)
YIN QUN (CN)
YAN RONGMEI (CN)
LI QIAN (CN)
WANG YAN (CN)
Application Number:
PCT/CN2022/134868
Publication Date:
June 08, 2023
Filing Date:
November 29, 2022
Export Citation:
Assignee:
SUZHOU ALPHAMAB CO LTD (CN)
International Classes:
A61P7/02; A61K39/395; C07K16/36; C07K16/46
Domestic Patent References:
| WO2022002233A1 | 2022-01-06 | |||
| WO2017127468A1 | 2017-07-27 | |||
| WO2017218371A1 | 2017-12-21 |
Foreign References:
| CN113880949A | 2022-01-04 | |||
| CN113880950A | 2022-01-04 | |||
| CN113880951A | 2022-01-04 |
Other References:
LORENTZ, C. U. ET AL.: "The contact activation inhibitor and factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, vol. 39, no. 4, 30 April 2019 (2019-04-30), pages 799 - 809, XP093017816, DOI: 10.1161/ATVBAHA.118.312328
Attorney, Agent or Firm:
SHANGHAI DIANSHI PARTNERS, P.C. (CN)
Download PDF: